A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-Agent Maintenance Versus Rituximab in Subjects With Relapsed/Refractory Follicular, Marginal Zone, or Mantle Cell Lymphoma.
Location: REDI (East Bay)
Please contact Vivian Leong LeongV@sutterhealth.org about MAGNIFY
Please note that trial statuses change frequently, for the most up to date information regarding REDI's enrolling studies; please contact the research department at 510-204-5571.
Investigator: Su-Ying Liang, Ph.D.
Investigator: Jiang Li, Ph.D., MPH